https://doi.org/10.1200/jco.2011.39.0823
F
Federico Piacentini
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
249
Papers
3.6K
Citations
29
h-index
72
i10-index
Federico Piacentini is an academic researcher from University of Modena and Reggio Emilia. The author has contributed to research in topics: HER2/EGFR in Cancer Research & Advanced Breast Cancer Therapies & Breast Cancer Treatment Studies. The author has an h-index of 29, co-authored 212 publications.
ORCID: 0000-0001-8969-638XPapers by this author
worksPreoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study
2012 · Journal of Clinical Oncology · 366 citations
Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-Institution analysis
2012 · Annals of Oncology · 192 citations
https://doi.org/10.1093/annonc/mds248
Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial
2016 · Annals of Oncology · 156 citations
https://doi.org/10.1093/annonc/mdw262
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study
2018 · Annals of Oncology · 152 citations
https://doi.org/10.1093/annonc/mdy414
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients
2013 · Annals of Oncology · 140 citations
https://doi.org/10.1093/annonc/mdt364
Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial
2015 · The Lancet Oncology · 127 citations
https://doi.org/10.1016/s1470-2045(15)00373-3
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat